COLL - Collegium Pharmaceutical, Inc.
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 15.78 |
| Open | 16.29 |
| Bid | 15.76 x 1000 |
| Ask | 15.86 x 800 |
| Day's Range | 15.77 - 15.77 |
| 52 Week Range | 10.10 - 25.59 |
| Volume | 4,302 |
| Avg. Volume | 421,607 |
| Market Cap | 541.479M |
| Beta (5Y Monthly) | 1.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.38 |
| Earnings Date | Aug 05, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.43 |
- Zacks
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Collegium to Host Conference Call to Discuss Second Quarter 2020 Financial Results and Provide Corporate Update
STOUGHTON, Mass., July 21, 2020 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on.
- Zacks
AMRX vs. COLL: Which Stock Should Value Investors Buy Now?
AMRX vs. COLL: Which Stock Is the Better Value Option?
- Insider Monkey
Hedge Funds Keep Buying Collegium Pharmaceutical Inc (COLL)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of March 31st, 2020. […]
- GlobeNewswire
Collegium Pharmaceutical Named one of Boston Business Journal’s 2020 Best Places to Work
Collegium Pharmaceutical, Inc. (COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has been named one of Boston Business Journal’s 2020 Best Places to Work. “We are honored to be recognized by the Boston Business Journal, and importantly, by our employees, as one of Boston’s best places to work,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “At Collegium, we are fortunate to have a remarkably talented team of people who are committed to upholding our core values and dedicated to our mission of becoming the leader in responsible pain management.”
- Zacks
AMRX or COLL: Which Is the Better Value Stock Right Now?
AMRX vs. COLL: Which Stock Is the Better Value Option?
- Thomson Reuters StreetEvents
Edited Transcript of COLL earnings conference call or presentation 7-May-20 8:30pm GMT
Q1 2020 Collegium Pharmaceutical Inc Earnings Call
- Motley Fool
2 Value Stocks That Will Make You Richer in May
Let's examine two value stocks that can make you richer in May. AbbVie (NYSE: ABBV) is a blue-chip pharmaceutical company trading at just eight times forward earnings. The company's flagship product is Humira, a drug that treats a variety of diseases, such as Crohn's disease, rheumatoid arthritis, and ulcerative colitis.
- Motley Fool
Collegium Pharmaceutical Inc (COLL) Q1 2020 Earnings Call Transcript
You are cautioned that such forward-looking statements involve risks and uncertainties, including and without limitation, the impact of the COVID-19 pandemic, the risks that we may not be able to successfully commercialize Xtampza ER and the Nucynta franchise, and that we may incur significant expense and may not prevail in current or future opioid industry litigation and investigation, patent infringement litigation or other litigation pertaining to our products. Thank you, Alex.
- Simply Wall St.
The Collegium Pharmaceutical (NASDAQ:COLL) Share Price Is Up 116% And Shareholders Are Boasting About It
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) shareholders might be concerned after seeing the share price drop 20% in...
- GlobeNewswire
Collegium Reports First Quarter 2020 Profitability
– Achieves GAAP Profitability with $0.5 Million in Net Income in the First Quarter of 2020 – – Non-GAAP Net Income of $31.2 Million in the First Quarter of 2020 – – Xtampza®.
- GlobeNewswire
Collegium to Host Conference Call to Discuss First Quarter 2020 Financial Results and Provide Corporate Update
STOUGHTON, Mass., April 23, 2020 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on.
- GlobeNewswire
Collegium to Participate in Upcoming Investor Conference
STOUGHTON, Mass., April 07, 2020 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain.
- Thomson Reuters StreetEvents
Edited Transcript of COLL earnings conference call or presentation 27-Feb-20 9:30pm GMT
Q4 2019 Collegium Pharmaceutical Inc Earnings Call
- GlobeNewswire
Collegium Reports Full-Year 2019 Revenue of $296.7 Million
– 2019 Revenue Growth of 6%, Driven by Xtampza ER revenue growth of 51% – – Xtampza® ER Prescriptions Grew 49% in 2019 – – Collegium Guides to Profitability in 2020 – –.
- GlobeNewswire
Collegium to Host Conference Call to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Provide Corporate Update
STOUGHTON, Mass., Feb. 26, 2020 -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain.
- GlobeNewswire
Collegium Announces Closing of the Nucynta Franchise Acquisition
Collegium Pharmaceutical, Inc. (COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, announced today the closing of its previously announced acquisition of the Nucynta franchise from Assertio Therapeutics, Inc. Jefferies LLC acted as financial advisor to Collegium on the transaction, and Pepper Hamilton LLP served as legal counsel. In support of the Nucynta acquisition, Collegium also announced today the funding of its previously announced $200.0 million senior secured term loan from BioPharma Credit PLC (“loan”) and the closing of its previously announced underwritten public offering of $143.75 million aggregate principal amount of 2.625% convertible senior notes due 2026 (“notes”), which includes the full exercise by the underwriter of an option to purchase an additional $18.75 million in aggregate principal amount of notes to cover over-allotments.
- GlobeNewswire
Collegium Pharmaceutical, Inc. Prices $125.0 Million Convertible Senior Notes Offering
Collegium Pharmaceutical, Inc. (COLL) today announced the pricing of its offering of $125,000,000 aggregate principal amount of 2.625% convertible senior notes due 2026 (the “notes”) in a public offering registered under the Securities Act of 1933, as amended. Collegium also granted the underwriter of the notes a 30-day option to purchase up to an additional $18,750,000 principal amount of notes solely to cover over-allotments.
- GlobeNewswire
Collegium Pharmaceutical, Inc. Announces Proposed Convertible Senior Notes Offering
Collegium Pharmaceutical, Inc. (COLL) today announced its intention to offer, subject to market and other conditions, $125,000,000 aggregate principal amount of convertible senior notes due 2026 (the “notes”) in a public offering registered under the Securities Act of 1933, as amended. Collegium also expects to grant the underwriter of the notes a 30-day option to purchase up to an additional $18,750,000 principal amount of notes solely to cover over-allotments. Collegium will settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at Collegium’s election.
- Simply Wall St.
What Kind Of Share Price Volatility Should You Expect For Collegium Pharmaceutical, Inc. (NASDAQ:COLL)?
Anyone researching Collegium Pharmaceutical, Inc. (NASDAQ:COLL) might want to consider the historical volatility of...
- Benzinga
The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 6) Acceleron Pharma Inc (NASDAQ: XLRN ) Alector Inc (NASDAQ: ...
- GlobeNewswire
Collegium to Acquire U.S. Rights to Nucynta Franchise
Collegium Pharmaceutical, Inc. (COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that it has entered into a definitive agreement to acquire the U.S. rights to the Nucynta Franchise from Assertio Therapeutics, Inc. (“Assertio”) for $375.0 million in cash. “Acquiring the full U.S. rights to the Nucynta Franchise is financially transformative for Collegium,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. Collegium will assume the U.S. license for the Nucynta Franchise, and will no longer be required to pay royalties to Assertio.
- PR Newswire
Biohaven Appoints Michael Heffernan To Board Of Directors
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced the appointment of Michael Heffernan to its Board of Directors ("Board").
- Zacks
Prospects Appear Bright for Small Drug Industry in 2020
Prospects Appear Bright for Small Drug Industry in 2020
- Zacks
Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
